fashion -WSS

fashion

author：knowledge 2025-09-29 21:27:02 - browse：4

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： FDA panel issues narrow recommendation for Covid vaccine booster doses

WSS

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

Phenylephrine and the overlooked value of the placebo effect

Histogen: Failed biotech offers rare public look inside

3 questions for the future of Biden's cancer moonshot

What to know about Virgin Galactic's 1st mission taking paying customers to space

leisure time

fashion

hotspot

Virginia high school admissions case could be legal follow

FDA rejects Alnylam's heart disease treatment over insufficient data

State Dept. review finds Biden bears some blame for Afghanistan failures

Maui's cultural, historic landmarks damaged in the devastating wildfires

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Bristol 'take

Psychedelics group wrestles with new pharma identity

How to use technology to prevent future drug shortages

Activists slam private health insurers over coverage restrictions

Bristol 'take

Wikipedia

Wegovy’s successful heart trial raises vital question about weight loss

A virus, fished out of a lake, may have saved a man’s life

Bill would stop addiction treatment from triggering child abuse inquiry

Sana to lay off nearly a third of staff, de

The best solution to the drug shortages problem

Q&A: Figuring out how songbirds sing may lead to better understanding of how humans learn

entertainment

entertainment

leisure time

hotspot